|
BioMimetic Therapeutics to Highlight Corporate Activities at Pacific Growth Equities Life Science Growth Conference Franklin, Tenn. – June 8, 2006 - BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that Charles E. Hart, Ph.D., chief scientific officer, plans to provide an overview of corporate activities at the Pacific Growth Equities Life Sciences Growth Conference. The conference will take place at the InterContinental Mark Hopkins Hotel in San Francisco on Tuesday, June 13 at 10:30 a.m. Pacific Time. A live audio webcast of the presentation will be available in the Investor Information area. The webcast will be accessible for a period of 30 days. About BioMimetic Therapeutics BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) is developing and commercializing bio-active drug-device combination products for the healing of musculoskeletal injuries and disease, including periodontal, orthopedic, spine and sports injury applications. BioMimetic received marketing approval from the FDA for its first product as a grafting material for bone and periodontal regeneration following completion of human clinical trials, which demonstrated the safety and efficacy of its platform technology in this indication. The Company's product and product candidates all combine recombinant protein therapeutics with tissue specific scaffolds to actively stimulate tissue healing and regeneration. BioMimetic's product pipeline is designed to provide new treatment options to improve the quality of life for millions of patients suffering injuries or deterioration of the bones, cartilage, ligaments and tendons. Forward-looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the current intent and expectations of the management of BioMimetic Therapeutics. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. BioMimetic's actual results and the timing and outcome of events may differ materially from those expressed in or implied by the forward-looking statements because of risks associated with our unproven preclinical and clinical development activities, regulatory oversight, intellectual property claims, litigation and other risks detailed in the company's filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its registration statement on Form S-1. Except as required by law, BioMimetic undertakes no responsibility for updating the information contained in this press release beyond the published date, whether as a result of new information, future events or otherwise, or for changes made to this document by wire services or Internet services. . For further information, contact Kearstin Patterson, manager corporate communications, at 615-236-4419. |